Business Wire

ForumPay Joins Forces with ZBX to Bring Crypto Payments to Malta’s Gaming Industry

16.8.2021 14:07:00 EEST | Business Wire | Press release

Share

ForumPay, the global cryptocurrency payments technology provider is delighted to announce a partnership with ZBX, the Maltese crypto exchange to enable the 250 million plus crypto wallet holders around the world to use their crypto for deposits with local iGaming sites.

The partnership with ZBX, a Class 4 VFA Service Provider with the MFSA (Malta Financial Services Authority) enables ForumPay to offer the first fully compliant crypto payments solution for MGA (Malta Gaming Authority) licensed gaming operators and their players.

Thanks to this collaboration, the depositing experience is even easier than using a credit card. To make a deposit with their favorite crypto and wallet a player simply scans the QR code presented in the online cashier. The crypto is instantly converted into FIAT at the best available exchange rate for deposit into the player’s account.

After this quick step, the iGaming site will automatically be notified of the crypto equivalent in FIAT awarded to the player so that they can access the funds immediately for play. This hassle-free process is a major milestone for crypto adoption in the gaming world, as it lets crypto holders convert just the amount they plan on betting with.

The tie up comes after the executive teams of both companies spent time with the regulators to establish a crypto payments flow which is sensitive to the KYC and AML demands on the gaming operators and meets the requirements of the MGA and MFSA.

Josh Tate, CEO and co-founder of ForumPay said, “It is exciting to work with such innovative companies and regulators to meet a massive demand in the marketplace from both operators and players. Facilitating crypto payments in the iGaming space has major benefits, such as amplifying the player base, fraud protection for casinos through instant verification of funds, and paving the way for the mass adoption of cryptocurrency in a fully compliant environment.”

Ian Dawson, CFO of ZBX said, “We are privileged to be a part of the growing crypto iGaming ecosystem in Malta. It is exciting for us to explore the full use cases of both our technology and the VFA Act in the provision of fiat-crypto solutions with ForumPay. We fully expect that the harmonization of crypto technology, regulation and services will improve and increase, and we look forward to working with world leading businesses in the provision of our services.”

ForumPay is a complete cryptocurrency to fiat payment technology firm. Our core processing technology helps businesses attract new customers, optimize customer’s ability to spend and increase revenue by embracing the 250+ million crypto consumers around the world. Our wallet agnostic solution enables the entire crypto consumer community to spend with their preferred cryptocurrency and from their preferred wallet for everyday goods and services. Our services eliminate the merchant’s exposure or risk by processing the transaction with instant conversion of the crypto into traditional currency. Our merchants simply receive their payments in the currency of their choice directly into their preferred bank account. The transactional experience is the same as accepting credit cards or other popular payment options, but simpler, faster, and more secure.

In today’s competitive environment, ForumPay is an excellent tool for businesses to gain a serious competitive advantage with the fastest growing consumer segment in the world. There were more than 5.6 million wallets downloaded in January of this year alone. Studies show that 40% of the consumers that spend crypto with merchants are in fact new customers, hence our characterization of ForumPay as a customer acquisition tool. Additionally, crypto consumers are shown to spend 2x AOV that of a typical credit card consumer illustrating the attractive, affluent demographic.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Paul Wordsworth – Director of Global Account Management
paul@forumpay.com

Joaquín de Miguel – Marketing Director at ForumPay
joaquin@forumpay.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye